Beamtree Holdings Limited

BMT.ASX

Health Care

To provide a proprietary subscription based Clinical Decision Support system (CDS) designed to provide health professionals with assistance in clinical decision-making tasks.

Market Data

Price

$0.096

+0.0%
Market Cap

$27.3M

P/E Ratio

-100000.0x

EPS

$-0.020

Div. Yield

0.00%

52-Week Change

-0.5%

Latest Earnings

Appendix 4D and FY26 Interim Report

19 February 2026

Revenue
$14.53
+2.0% YoY
NPAT
-$2.87
+12.0% YoY
EPS
$-0.01

Beamtree Holdings Limited reported a 12% improvement in net loss to $2.9M for H1 FY26, with recurring revenue growing 10% to $13.5M and the company achieving operating profit of $61k versus $5k previously. The company is progressing AI-enabled products with customer trials and announced a strategic review to unlock shareholder value amid continued investment in international expansion. Key points: Recurring revenue grew 10% to $13.5M with near 100% client retention; Achieved operating profit of $61k, significant improvement from $5k previously; Multiple AI product milestones achieved including Evolve platform launch in UK NHS

Recent Announcements

7 May 2026 Sph Neutral

Becoming a substantial holder

ON BEHALF OF ITSELF AND EACH OF ITS ASSOCIATES IDENTIFIED IN became a substantial holder (5.047%).

6 Mar 2026 Sph Neutral

Becoming a substantial holder

Jakeco Pty Ltd ACN 091 847 317 trading as Di Marco Family Office (and became a substantial holder (6.3516%).

4 Mar 2026 Sph Neutral

Replacement - Ceasing to be a substantial holder from MIR

MIR ceased to be a substantial holder.

4 Mar 2026 Sph Neutral

Notice of ceasing to be a substantial holder from MIR

MIR ceased to be a substantial holder.

19 Feb 2026 Actual Results Neutral

Appendix 4D and FY26 Interim Report

Beamtree Holdings Limited reported a 12% improvement in net loss to $2.9M for H1 FY26, with recurring revenue growing 10% to $13.5M and the company achieving operating profit of $61k versus $5k previously. The company is progressing AI-enabled products with customer trials and announced a strategic review to unlock shareholder value amid continued investment in international expansion. Key points: Recurring revenue grew 10% to $13.5M with near 100% client retention; Achieved operating profit of $61k, significant improvement from $5k previously; Multiple AI product milestones achieved including Evolve platform launch in UK NHS

17 Feb 2026 Sph Neutral

Ceasing to be a substantial holder

This appears to be a blank Form 605 template for notifying when a substantial holder ceases to hold a substantial stake in a company, but no specific company, holder, or transaction details are provided.

Get real-time alerts for BMT

Receive AI-powered earnings summaries and instant notifications when Beamtree Holdings Limited releases results.

Register Free